Expression and significance of MiR-126 and VEGF in proliferative diabetic retinopathy

被引:16
|
作者
Liu, R. [1 ]
Liu, C-M [2 ]
Cui, L-L [1 ]
Zhou, L. [3 ]
Li, N. [1 ]
Wei, X-D [1 ]
机构
[1] Tangshan Worker Hosp, Dept Ophthalmol, Tangshan, Peoples R China
[2] Tangshan Worker Hosp, Dept Emergency Med, Tangshan, Peoples R China
[3] Tangshan Worker Hosp Grp Rehabil Hosp, Dept Ophthalmol, Tangshan, Peoples R China
关键词
MiR-126; VEGF; Proliferative diabetic retinopathy; GROWTH; NEOVASCULARIZATION; MICRORNA-126;
D O I
10.26355/eurrev_201908_18518
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To study the expression and significance of micro ribonucleic acid (miR)-126 and vascular endothelial growth factor (VEGF) in the vitreous body and proliferative membrane tissues of affected eyes and plasma in proliferative diabetic retinopathy (PDR). PATIENTS AND METHODS: A total of 50 PDR patients admitted to our hospital from January 2017 to January 2018 were collected, including 17 cases in stage IV, 20 cases in stage V, and 13 cases in stage VI according to the DR staging criteria. Another 30 patients with an idiopathic macular hole were selected as control group. After admission, the examinations were performed, venous blood was drawn, and vitrectomy was performed, during which the vitreous body and proliferative membrane tissues were taken. The plasma VEGF content was detected via enzyme-linked immunosorbent assay (ELISA). The VEGF protein expression level was detected via Western blotting in vitreous body and proliferative membrane tissues. Moreover, the miR-126 expression was detected via quantitative polymerase chain reaction (qPCR). RESULTS: In the vitreous body tissues, proliferative membrane tissues and plasma, the expression level of miR-126 was significantly lower in control group than that in stage IV, V, and VI groups (p<0.05). The miR-126 expression was significantly lower in stage IV group than that in stage V and VI groups (p<0.05), meanwhile, miR-126 expression was significantly lower in stage V group than that in stage VI group (p<0.05). In the vitreous body tissues, proliferative membrane tissues and plasma, the VEGF mRNA and protein expression levels were significantly higher in control group than those in stage IV, V, and VI groups (p<0.05). The VEGF expressions were significantly higher in stage IV group than those in stage V and VI groups (p<0.05). In addition, VEGF expressions were significantly higher in stage V group than those in stage VI group (p<0.05). Furthermore, the VEGF expression level was negatively correlated with the miR-126 expression level. CONCLUSIONS: We found that the abnormally high expression of miR-126 negatively regulates VEGF, which may be one of the important mechanisms of occurrence of PDR. The miR-126 and VEGF content can serve as important predictors for the condition of PDR.
引用
收藏
页码:6387 / 6393
页数:7
相关论文
共 50 条
  • [21] ALPHAB-CRYSTALLIN EXPRESSION IN EPIRETINAL MEMBRANE OF HUMAN PROLIFERATIVE DIABETIC RETINOPATHY
    Dong, Zhenyu
    Kase, Satoru
    Ando, Ryo
    Fukuhara, Junichi
    Saito, Wataru
    Kanda, Atsuhiro
    Murata, Miyuki
    Noda, Kousuke
    Ishida, Susumu
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (06): : 1190 - 1196
  • [22] Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy
    Nakamura, Shinko
    Iwasaki, Naoko
    Funatsu, Hideharu
    Kitano, Shigehiko
    Iwamoto, Yasuhiko
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (01) : 21 - 26
  • [23] A review of anti-VEGF agents for proliferative diabetic retinopathy
    Osaadon, P.
    Fagan, X. J.
    Lifshitz, T.
    Levy, J.
    EYE, 2014, 28 (05) : 510 - 520
  • [24] A decrease in VEGF and inflammatory markers is associated with diabetic proliferative retinopathy
    Blum, Arnon
    Socea, Dorina
    Ben-Shushan, Rotem Shelly
    Keinan-Boker, Lital
    Naftali, Modi
    Segol, Gila
    Tamir, Snait
    EUROPEAN CYTOKINE NETWORK, 2012, 23 (04) : 158 - 162
  • [25] Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy
    Jardeleza, Maria Stephanie R.
    Miller, Joan W.
    SEMINARS IN OPHTHALMOLOGY, 2009, 24 (02) : 87 - 92
  • [26] A review of anti-VEGF agents for proliferative diabetic retinopathy
    P Osaadon
    X J Fagan
    T Lifshitz
    J Levy
    Eye, 2014, 28 : 510 - 520
  • [27] Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma
    Salajegheh, Ali
    Vosgha, Haleh
    Rahman, Md Atiqur
    Amin, Moein
    Smith, Robert Anthony
    Lam, Alfred King-Yin
    HUMAN PATHOLOGY, 2016, 51 : 75 - 85
  • [28] Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review
    Tan, Yiran
    Fukutomi, Akira
    Sun, Michelle T.
    Durkin, Shane
    Gilhotra, Jagjit
    Chan, Weng Onn
    SURVEY OF OPHTHALMOLOGY, 2021, 66 (06) : 926 - 932
  • [29] Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population
    Roberto Gonzalez-Salinas
    Maria C Garcia-Gutierrez
    Gerardo Garcia-Aguirre
    Virgilio Morales-Canton
    Raul Velez-Montoya
    Vidal R Soberon-Ventura
    Victoria Gonzalez
    Rodrigo Lechuga
    Pablo Garcia-Solis
    David G Garcia-Gutierrez
    Marco Vinicio Garcia-Solis
    Manuel Saenz de Viteri
    Juan C Solis-S
    International Journal of Ophthalmology, 2017, (01) : 135 - 139
  • [30] Identification of VEGF-Independent Cytokines in Proliferative Diabetic Retinopathy Vitreous
    Bromberg-White, Jennifer L.
    Glazer, Louis
    Downer, Robert
    Furge, Kyle
    Boguslawski, Elissa
    Duesbery, Nicholas S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (10) : 6472 - 6480